30 related articles for article (PubMed ID: 17172818)
1. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
Huang L; Zhu C; Sun Y; Xie G; Mackenzie GG; Qiao G; Komninou D; Rigas B
Carcinogenesis; 2010 Nov; 31(11):1982-90. PubMed ID: 20627873
[TBL] [Abstract][Full Text] [Related]
2. Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations.
Steinbrink SD; Pergola C; Bühring U; George S; Metzner J; Fischer AS; Häfner AK; Wisniewska JM; Geisslinger G; Werz O; Steinhilber D; Maier TJ
Cell Mol Life Sci; 2010 Mar; 67(5):797-806. PubMed ID: 20091083
[TBL] [Abstract][Full Text] [Related]
3. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer.
Zhao H; Yi B; Liang Z; Phillips C; Lin HY; Riker AI; Xi Y
Genes Dis; 2021 May; 8(3):320-330. PubMed ID: 33997179
[TBL] [Abstract][Full Text] [Related]
4. The effect of sulindac on redox homeostasis and apoptosis-related proteins in melanotic and amelanotic cells.
Miliński M; Staś M; Rok J; Beberok A; Wrześniok D
Pharmacol Rep; 2023 Aug; 75(4):995-1004. PubMed ID: 37195561
[TBL] [Abstract][Full Text] [Related]
5. Increased survival rate by local release of diclofenac in a murine model of recurrent oral carcinoma.
Will OM; Purcz N; Chalaris A; Heneweer C; Boretius S; Purcz L; Nikkola L; Ashammakhi N; Kalthoff H; Glüer CC; Wiltfang J; Açil Y; Tiwari S
Int J Nanomedicine; 2016; 11():5311-5321. PubMed ID: 27789944
[TBL] [Abstract][Full Text] [Related]
6. Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors.
Li X; Pathi SS; Safe S
BMC Cancer; 2015 Dec; 15():974. PubMed ID: 26673922
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets.
Liggett JL; Zhang X; Eling TE; Baek SJ
Cancer Lett; 2014 May; 346(2):217-24. PubMed ID: 24486220
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation increases survival and modulates high risk HPV-induced phenotypes in oral squamous cell carcinoma cells and correlates with p53 mRNA transcriptional down-regulation.
Moody M; Le O; Rickert M; Manuele J; Chang S; Robinson G; Hajibandeh J; Silvaroli J; Keiserman MA; Bergman CJ; Kingsley K
Cancer Cell Int; 2012 Mar; 12():10. PubMed ID: 22443202
[TBL] [Abstract][Full Text] [Related]
9. Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury.
Zou W; Beggs KM; Sparkenbaugh EM; Jones AD; Younis HS; Roth RA; Ganey PE
J Pharmacol Exp Ther; 2009 Oct; 331(1):114-21. PubMed ID: 19638570
[TBL] [Abstract][Full Text] [Related]
10. High risk HPV types 18 and 16 are potent modulators of oral squamous cell carcinoma phenotypes in vitro.
Reddout N; Christensen T; Bunnell A; Jensen D; Johnson D; O'Malley S; Kingsley K
Infect Agent Cancer; 2007 Nov; 2():21. PubMed ID: 18001474
[TBL] [Abstract][Full Text] [Related]
11. Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition.
Bock JM; Menon SG; Goswami PC; Sinclair LL; Bedford NS; Domann FE; Trask DK
Mol Carcinog; 2007 Oct; 46(10):857-64. PubMed ID: 17415779
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ
Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825
[TBL] [Abstract][Full Text] [Related]
13. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines.
Han EK; Arber N; Yamamoto H; Lim JT; Delohery T; Pamukcu R; Piazza GA; Xing WQ; Weinstein IB
Breast Cancer Res Treat; 1998 Apr; 48(3):195-203. PubMed ID: 9598866
[TBL] [Abstract][Full Text] [Related]
14. Chemopreventive Efficacy of Sulindac Sulfone as a Selective Apoptotic Antineoplastic Drug in Human Head and Neck Squamous Cell Carcinoma Cell Lines: A Systematic Review.
Karuppiah N; B S; Chockalingam RM; Bhupathy PK; Kalaimani G; Ramamurthi R
Cureus; 2024 Jan; 16(1):e51692. PubMed ID: 38313951
[TBL] [Abstract][Full Text] [Related]
15. The role of p21Waf1/CIP1 as a Cip/Kip type cell-cycle regulator in oral squamous cell carcinoma (Review).
Pérez-Sayáns M; Suárez-Peñaranda JM; Gayoso-Diz P; Barros-Angueira F; Gándara-Rey JM; García-García A
Med Oral Patol Oral Cir Bucal; 2013 Mar; 18(2):e219-25. PubMed ID: 23385498
[TBL] [Abstract][Full Text] [Related]
16. Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition.
Bock JM; Menon SG; Goswami PC; Sinclair LL; Bedford NS; Jackson RE; Trask DK
Cancer Biol Ther; 2007 Jan; 6(1):30-9. PubMed ID: 17172818
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
